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Type 1 diabetes mellitus (T1DM) is an autoimmune disease manifested by an autoimmune attack 
on pancreatic beta-islet cells. T1DM can occur at any age. However, it is most often diagnosed in 
children, adolescents, or young adults. My thesis is derived from a large longitudinal study of 
Juvenile Onset Diabetes (JOD) at Children’s Hospital of Pittsburgh. The objectives are: 1) Data 
cleaning and preliminary summary of the cohort with respect to T-cell data. 2) Evaluating the T-
cell data criteria used for the prediction of the diabetes.  
An extensive data examination was made for accuracy and consistency. A preliminary 
summary of the stimulation index (SI) for the test analytes and the number of positive antigens 
was performed by demographic sub-groups, HLA-DQ serotype, and follow up time. Using the 
ROC analysis, an evaluation of diagnosis test performance based on two different criteria was 
performed. 
The JOD dataset had few errors with an error rate under 0.5%. The accuracy and 
consistency of the data is good. New onsets and first degree relatives (FDRs) nonconverters had 
a relatively stable SI as well as positive antigen tests results. The SI level and positive test results 
are higher in new onsets when compared with FDRs. FDR-converters (those subsequently 
developing diabetes) prior to using insulin have SIs and number of positive antigens similar to  
FDR-nonconverters; and FDR-converters after starting insulin have results similar to  new 
onsets. The recommended SI cutoff of 1.5 indicating positive response appears reasonable. 
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However, the cutoff still may be optimized for better prediction. Evidence suggests that a lower 
cutoff within 1.25 to 1.5 may be better and the number of positive antigens could move from >4 
to greater than 5 or 6. 
Public health significance: Development of a better understanding of the pattern of T-cell 
response in diabetes and non-diabetic children, and those progressing to diabetes, may give us 
tools to predict the early onset of disease. It is this point in time where therapeutic intervention 
could be focused to help stem the development of T1DM or to dramatically reduce its severity. 
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1.0  INTRODUCTION 
A cohort design is a study in which patients who presently have a specified condition and/or 
receive a particular treatment are followed over time and compared with another group who are 
not affected by the condition under investigation. The cohort study is a form of long-term study 
often used in medicine, social science, actuarial science, and ecology. In a study of juvenile onset 
diabetes at Children’s Hospital of Pittsburgh (CHP), we have observational data on a subset of 
1,591 participants who have more than four years of follow up. The purpose of this thesis are 
two fold; 1) Perform data cleaning to detect and correct the potential mistakes in the original 
data, transforming the raw data into a form that allows statistical analysis, and the generating of 
the preliminary summary of the t-cell data for further analysis. 2) Perform ROC analysis for 10 
test-antigens and to discuss the criteria for the prediction of type 1 diabetes mellitus. 
1.1 OVERVIEW OF DIABETES MELLITUS  
Diabetes mellitus is a group of metabolic diseases in which the body has trouble regulating its 
blood sugar (glucose) levels, either from the body not producing enough insulin, or as a result of 
cells not responding to the insulin that is produced. Either condition produces high blood sugar 
and the typical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and 
polyphagia (increased hunger) [1]. Diabetes mellitus occurs throughout the world, but is more 
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common in the more developed countries. In 2010, an estimated 285 million people had diabetes 
[2]. There are 25.8 million people who have diabetes in the United States, of whom 7 million 
people remain undiagnosed. Another 57 million people are estimated to have prediabetes [3]. 
Based on the known causes and risk factors of the disease, there are three major types of 
diabetes mellitus: Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), and 
Gestational Diabetes Mellitus (GDM). Briefly, T1DM is an immune disorder in which the body 
attacks and destroys insulin-producing beta cells in the pancreas; T2DM is a metabolic disorder 
that is characterized by high blood glucose in the context of insulin resistance and relative insulin 
deficiency. This is in contrast to diabetes mellitus type 1 in which there is an absolute insulin 
deficiency; GDM is a form of glucose intolerance during pregnancy without a previous diagnosis 
of diabetes. 
1.2 TYPE 1 DIABETES MELLITUS  
T1DM can occur at any age, but it is most often diagnosed in children, teens, or young adults, so 
T1DM was originally referred to as Juvenile-Onset Diabetes. T1DM causes an estimated 5–10% 
of all diabetes cases worldwide [4]. Incidence varies from eight to 17 per 100,000 in Northern 
Europe and the U.S., with a high of about 35 per 100,000 in Scandinavia, to a low of one per 
100,000 in Japan and China [5]. 
The exact cause of T1DM is unknown. Most likely it is induced by one or more of the 
following: genetic susceptibility, a diabetogenic trigger and/or exposure to a driving antigen [6]. 
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1.3 HLA AND HLA – DQ TYPE IN T1DM 
1.3.1 Human leukocyte antigen (HLA) 
Human leukocyte antigens (HLA) are proteins that are present on the surface of our bodies' cells. 
Depending on the HLA proteins displayed on the surface of our cells, the immune system 
recognizes our own cells as “self”, as opposed to “foreign”. In humans, HLA also is called Major 
Histocompatibility Complex (MHC). The HLA types are genetically determined; the 
corresponding genes to HLA proteins are located on chromosome 6. Different clusters of genes 
form three major classes of HLA based on their functions [7-8]: 
Class I antigens (A, B & C) present peptides from inside the cell (including viral peptides 
if present). The proteins produced from these genes are present on the surface of almost all cells. 
MHC class I proteins display these peptides to the immune system. If the immune system 
recognizes the peptides as foreign (such as viral or bacterial peptides), it responds by triggering 
the infected cell to self-destruct. 
Class II antigens (DP, DM, DOA, DOB, DQ, and DR) corresponding to MHC class II 
genes, which provide instructions for making proteins that are present almost exclusively on the 
surface of certain immune system cells. These proteins also display peptides to the immune 
system like MHC class I proteins. 
Class III antigens corresponding to MHC class III genes have somewhat different 
functions; they are involved in inflammation and other immune system activities. The functions 
of some MHC genes are unknown. (See Figure 1) 
4 
 
Figure 1. HLA region on Chromosome 6  
(by Xie et al.[9]) 
 
1.3.2 HLA-DQ 
HLA-DQ (DQ) is a cell surface type protein found on antigen presenting cells. It has an α chain 
and β chain which are coded by HLA-DQA1 and HLA_DQB2 genes, respectively. The two 
chains form a αβ heterodimer, where two chains vary greatly. The variance of subunit in α chain 
and β chain result in lots of different isoforms of DQ in human. Compared with α chain, the β 
chain has more forms of subunits and it helps us to discriminate the serotype of DQ.  The current 
serotype of DQ include HLA-DQ2, -DQ3, -DQ4, -DQ5, -DQ6, -DQ7, -DQ8, -DQ9. DQ help the 
immune system to recognize and present foreign antigens on the cells’ surface. It is believed that 
DQ also recognizes and presents self-antigens in order to develop tolerance for the immune 
system. However, the absent of tolerance to self-proteins incurs the autoimmune disease 
associated with DQ. For instance, DQ is involved in celiac disease [10] and T1DM. 
Recent  studies  have  demonstrated  that  some  HLA-DQ  genes  are  most  strongly  
associated  with  T1DM susceptibility [11-14]. A combination of DQ2 and DQ8 genes would 
increase the risk of adult onset Type 1 Diabetes and ambiguous type I/II Diabetes [15][16]. 
5 
1.3.3 Autoantibodies 
Autoantibodies are antibodies (immune proteins) that falsely target and damage specific tissues 
or organs of the body. One or more autoantibodies may be produced by a person's immune 
system when it fails to distinguish between "self" and "foreign" proteins. That is to say, the 
immune system disorder has a certain association with autoantibodies when the immune system 
ceases to recognize the self-components. Specific autoantibodies are usually present in a 
percentage of people with a particular autoimmune disorder, so several autoantibodies tests can 
be performed to predict or diagnose the autoimmune disorder. One of the most common 
immunologic markers of individuals with autoimmune diabetes is the presence of autoantibodies 
against beta-cell autoantigens. 
Diabetes-related (islet) autoantibody testing is primarily ordered to help distinguish 
between autoimmune type 1 diabetes and diabetes as a result of other causes. There are four 
common autoantibody tests used to distinguish between type 1 diabetes and diabetes resulting 
from other causes; ICA (Islet Cell Cytoplasmic Autoantibodies), recognizing islet cytoplasmic 
antigens, were detected many years ago in newly-diagnosed type 1 diabetic patients [17]. ICA 
can be present in 90% of type 1 diabetes patients at the time of diagnosis [18]. GADA (Glutamic 
Acid Decarboxylase Autoantibodies) has been found in approximately 50-80% of newly 
diagnosed type 1 diabetic patients [19-23]. IA-2A (Insulinoma-Associated-2 Autoantibodies) is 
found in about 55-80% of newly diagnosed type 1 diabetic patients [19,22,24]. IAA (Insulin 
Autoantibodies) is found in about 40-70% of newly diagnosed type 1 diabetic children.  
ICA was previously widely used to study the clinical course and pathogenesis of type 1 
diabetes. However, as the detection methods developed, ICA was replaced by GADA and IA-2A 
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in a large extent. Recently, autoantibodies against ZnT8 (ZnT8A) were discovered as an 
additional marker for type 1 diabetes [25]. 
7 
2.0  MATERIALS AND METHODS 
The juvenile onsets diabetes (JOD) cohort is a longitudinal cohort of new onsets with T1D and 
their first degree relatives (FDRs) initially without T1D. This study has been ongoing for over 30 
years. New onsets are identified upon presentation with T1DM to Children’s Hospital of 
Pittsburgh (CHP). The data for this thesis is derived from a subset of new onsets and their FDRs 
enrolled from January 2004 through June 2008, and who have results of T-cell data.  
2.1 STUDY DATASET CREATION  
Three datasets contained various information about the study participants. Information was 
extracted and merged into a single study dataset according the routine in Figure 2.   
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Figure 2. Study dataset creation 
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2.2 NEW VARIABLES CREATION 
2.2.1 Important analytes and terms from original data 
H.M. Dosch et al., introduced an assay system to make the detection of 14 antigens associated 
with T1DM [26]. Fourteen anlytes and cells alone were measured from the participants’ blood 
draw samples (Table 1), including 10 test antigens, 2 positive controls and 2 negative controls. 
Specific terms and criteria displayed in Table 2.  
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Table 1. Description for cells alone and 14 analytes 
Analytes Contents Useage 
CNSA_MBP Myelin Basic Protein (MBP), a myelin autoantigen 
commonly targeted in T1D & MS, (5µg/ml) 
test antigen 
CNSA_EX2 A major MBP autoimmune target epitope peptide (splice 
variant) expressed in developing myelin and remyelination 
only (5µg/ml) 
test antigen 
GLIA_GFAP Glial Fibrillary Acidic Protein, A glial autoantigen often 
targeted in T1D & MS (0.5µg/ml) 
test antigen 
GLIA_S100 A glial autoantigen often targeted in T1D and MS (0.5µg/ml) test antigen 
ISLA_Gad Glutamic Acid Decarboxylase, a T1D target autoantigen 
(5µg/ml) 
test antigen 
ISLA_Gad55 A GAD epitope peptide often targeted in T1D, also 
recognized by Nepom MHC class II tetramer (5µg/ml) 
test antigen 
ISLA_PI Pro-Insulin (1µg/ml) test antigen 
ISLA_Tep69 An ICA69 autoantigen peptide often targeted in T1D, 2 way 
mimicry antigen crossreactive with ABBOS (5µg/ml) 
test antigen 
MIP_Abbos ABBOS - a milk epitope peptide commonly targeted in T1D, 
2-way mimicry antigen ICA69 (5µg/ml) 
test antigen 
MIP_BSA Bovine Serum Albumin - cow milk protein (5µg/ml) test antigen 
PS_PHA T-cell mitogen (Phytohemagglutinin) (1µg/ml) positive control, 
proliferation 
competence 
PS_TT: Tetanus Toxin (0.1µg/ml) positive control, 
post-vaccination 
response 
competence 
OVA Ovalbumin - dietary protein (5µg/ml) negative control 
CSA_Actin Human Actin (5µg/ml) negative control 
Cells alone Back ground control 
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Table 2. Specific terms and criteria from original data for cells alone and 14 analytes 
Term Contents and Criteria 
Well1 counts per minute (cpm) 
Well2 counts per minute (cpm) 
WellMean mean cpm of Well1 and Well2 
SI Stimulation index (mean cpm experimental/ mean cpm cells alone) 
Result For test antigens, 
SI >= 1.5 is Positive, 
SI < 1.5 is Negative 
Interpretation For any given sample,  
with >= 4 positive responses to test antigens=Affected 
Less than 4 positive responses to test antigens = Unaffected 
 
2.2.2 Data cleaning variables creation 
The original dataset contained many hand calculations and as a result, potential mistakes could 
exist. In order to address this issue, it is important to recalculate and verify these values. 
Sequences of variables were generated to verify these calculations: 
1. Based on formula WellMean= (Well1+Well2)/2, for each of the analytes tested, a 
“wellmean_chk” variable was generated to check these calculations. 
2. Based on formula SI=WellMean/ (WellMean in cells alone), for each of analytes 
tested, a “SI_chk” variable was generated to check these calculations. 
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3. Based on the criterion “SI>=1.5 indicates a positive result for test antigen, SI<1.5 
indicates a negative result for the test antigen”; a “Result_chk” variable was 
generated for each of the test antigen. 
4. Based on the criterion that “for any given sample, with 4  or more positive responses 
to the test antigens indicates an affected sample, less than 4 positive responses to the 
test antigens indicates the sample unaffected”; an “Interpretation_chk”   variable was 
generated for each blood draw test. 
2.2.3 Preliminary summary and ROC analysis variables creation 
Several variables were created to perform preliminary summaries and ROC analysis. 
Age calculated at the participants’ first blood draw. 
Time window “win_ddx” was created based on the diagnosis date of T1DM for new-
onsets. We stratified the time interval from date of diagnosis to each blood draw date into several 
month categories. For the first degree relatives (FDRs) of the new onsets would we used their 
corresponding new onsets’ diagnosis date to generate these time windows. FDRs without new 
onsets records were coded as missing. 
Time windows “win_bdd” was created to stratify the time interval from first blood draw 
date to subsequent follow-up blood draw dates and grouped them into several month categories. 
Based on the blood draw date, a time sequencing variable “order” was created to indicate 
the progression of blood draw times in participants. 
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2.3 THE ROC METHOD  
The accuracy of antigens test to discriminate T1DM cases from normal cases is evaluated using 
Receiver Operating Characteristic (ROC) curve analysis. 
Usually we consider the results of an antigen test in two populations, one population with 
T1DM, the other population without T1DM; you will rarely observe a perfect separation between 
the two groups. Inevitably, the distribution of the test results will overlap, as depicted in the 
following table. 
 
Table 3. Distribution of diagnosis test result 
 T1DM Present T1DM Absent  
Test + a c a + c 
Test - b d b + d 
  a + b c + d   
 
 Several indices can be derived from Table 3.  
Sensitivity, also known as true positive rate (TPR), is the probability of a positive test 
result when the disease is present. Sensitivity = a / (a+b). Sensitivity relates to the test's ability to 
identify diseased individuals. If a test has high sensitivity, a positive result would more likely 
indicate the presence of disease. 
Specificity, also known as true negative rate, is the probability of a negative test result 
when the disease is not present. Specificity = d / (c+d). Specificity relates to the ability of the test 
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to identify disease free individuals. If a test has high specificity, a negative result would more 
likely suggest the absence of disease. 
Positive predictive value (PPV) is probability that the disease is present when the test is 
positive. PPV= a / (a+c). A high PPV would help a given test to conform the presence of disease 
when a positive result is yielded. 
Negative predictive value (NPV) is probability that the disease is not present when the 
test is negative. NPV= d / (b+d). A high NPV would help a given test to conform the absence of 
disease when a negative result is yielded. 
Note that PPV and NPV are both depended on prevalence [27], PPV and NPV should 
only be used if the ratio of the number of patients in the disease group and the number of patients 
in the healthy control group used to establish the PPV and NPV is equivalent to the prevalence of 
the diseases in the studied population. Otherwise, positive and negative likelihood ratios would 
be more accurate than PPV and NPV due to the likelihood ratios do not depend on prevalence.  
LR+ is a ratio between the probability of a positive test result given the presence of the 
disease and the probability of a positive test result given the absence of the disease,  
LR+ = True positive rate / False positive rate = Sensitivity / (1-Specificity). 
LR- is a ratio between the probability of a negative test result given the presence of the 
disease and the probability of a negative test result given the absence of the disease,  
LR- = False negative rate / True negative rate = (1-Sensitivity) / Specificity.   
The greater the value of LR+, the more likely a positive test result is from a diseased 
individual.  The greater the value of LR-, the more likely a negative test result is from a disease 
free individual.   
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The ROC curve has long been used to depict the tradeoff between true positive rates and 
false positive rate in signal detection theory [28]. Given different cutoff points, sensitivity is 
plotted with accompanying false positive rate (1- specificity) in a ROC curve (Figure 3). 
 
Figure 3. Example of a ROC curve 
  From Figure 3, we see that each point on the ROC curve represents a 
sensitivity/specificity pair corresponding to a particular decision threshold. Ideally, a test with 
perfect discrimination would have a ROC curve that passes through the upper left corner (100% 
sensitivity, 100% specificity). Therefore the closer the ROC curve is to the upper left corner, the 
higher the overall accuracy of the test [29]. 
The area under the ROC curve (AUC) is one way to quantitate the goodness or accuracy 
of diagnosis test in discriminating between 2 states of health.  A diagnosis test with no predictive 
value would have an AUC of 0.5 (also represented by the diagonal “chance” line above), while a 
diagnosis test with perfect discrimination would have an AUC of 1.  The empirical AUC is 
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calculated via the “trapezoidal” rule, where a trapezoid is constructed from the lines drawn for 
each two consecutive points on the curve (Figure 4).  The AUC would refer to the sum of areas 
of the trapezoids.  Mathematically, the AUC may be defined as  
1
0
( )AUC Sn t dt= ∫  
where t is the false positive rate, Sn(t) is the corresponding sensitivity [30]. 
 
Figure 4. Illustration of trapezoidal rule 
A general guide for determining the accuracy of a diagnostic test is the traditional 
academic point system [31]: (Table 4) 
Table 4. Accuracy classification by AUC for a diagnostic test 
Range of AUC Classification 
0.90-1  Excellent 
0.80-0.90 Good 
0.70-0.80 Fair 
0.60-0.70 Poor 
0.50-0.60  Fail 
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The AUC of a diagnosis is often compared to chance which has an AUC of 0.5.  The 
statistical test involves estimating AUCtest - AUCchance which is asymptotically normal.  With 
Gaussian techniques, we can derive a p-value under null hypothesis that the difference equals to 
zero. 
For the same study population, two diagnosis tests can also be compared using paired 
sample statistical techniques. The method exploits the mathematical equivalence of the AUC to 
the Mann-Whitney U-statistic [32].  According to this method, the comparison for ROCs of any 
two diagnosis test can be made by evaluating the difference of the AUCs which consider as 
asymptotically normal. 
Statistical Analysis System (SAS) version 9.2 was used for all data cleaning, descriptive 
statistics, test statistics, and graphics. 
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3.0  ANALYSIS AND RESULTS   
3.1 DATA CLEANING  
3.1.1 Checking missing value 
One of the first and most important steps in any data processing task is to verify that your data 
values are correct or, at the very least, conform to some set of rules.  After the creation of the 
study dataset, it is important to look through the whole dataset to find missing values before we 
process with the recalculations.  
In the study dataset, there are 31 observations whose well1 and well2 values for all 15 
analytes are missing. (See Table 18) These missing values are the result of a bad sample, or 
hemolysis of the sample. One observation sample only missed 1 record in CSA_Actinwell1 or 
CSA_Actinwell2. The reason for this missing datum was unknown. 
3.1.2 Recalculation for WellMean 
There are 6 observations which contained miscalculated WELLMEAN. (See Table 19 in 
Appendix A) 
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3.1.3 Recalculation for SI 
There are 29 observations which contained miscalculated SI (See Table 20 in Appendix A). 
3.1.4 Checking analytes’ result with corresponding SI 
For the 10 test antigens: CNSA_EX2, CNSA_MBP, GLIA_GFAP, GLIA_S100, ISLA_Gad, 
ISLA_Gad55, ISLA_PI, ISLA_Tep69, MIP_Abbos, MIP_BSA, the result should be positive, 
negative, or missing.  
If the dataset was correct, the SI value should match with its corresponding result. When 
the SI value of test antigen was >= 1.5, the result should be positive, or it was considered 
incorrect; When the SI value of test antigen < 1.5, the result should be negative, or it was 
considered incorrect. The result was considered as missing when the SI value was not reported. 
There are 20 mismatched results in total; 6 falsely reported as negative, and 14 falsely 
reported as positive (See Table 21, Table 22 in Appendix A). 
3.1.5 Checking analytes’ interpretation  
All analytes were interpreted as being affected, unaffected, or missing. 
A check of the analytes’ interpretation with corresponding number of positive test 
antigens was made. 
If the number of positive test antigens >= 4, they were interpreted as affected, or falsely 
unaffected. 
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If the number of positive test antigens < 4, they were interpreted as unaffected, or falsely 
affected. 
The interpretation was considered as missing when results were not reported. 
There are 23 mismatched interpretations in total; 18 false-unaffected interpretations, and 
5 false-affected (See Table 23, Table 24 in Appendix A). 
3.2 DEMOGRAPHICS  
The entire study population included 1,591 participants, 43.0% (685) of entire participants were 
males, and 57.0% (906) of entire participants were females. The complete population was made 
up of 95.8% (1,504) Whites, 2.3% (52) Blacks, 0.3% (4) Asians, and 0.6% (10) other or multiple 
races. There were 316 probands or new onsets, 1,275 first degree relatives (FDRs). FDRs were 
further subdivided into, FDR-converters and FDR-nonconverters. The FDR-converters are FDRs 
who converted/developed insulin dependent diabetes; the other, FDR-nonconverters are those 
FDRs who have not developed diabetes. The FDRs included 20 FDR-converters and 1,255 FDR-
nonconverters. Table 5 shows the distribution of gender in New Onsets, FDR-converters and 
FDR-nonconverters. 
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Table 5. Gender Distribution for Entire Population 
Gender New Onsets FDR-converters FDR-nonconverters Total 
 % (Counts) % (Counts) % (Counts) % (Counts) 
Male 59.5 (188) 40.0 (8) 39.0 (489) 43.0(685) 
Female 40.5 (128) 60.0 (12) 61.0 (766) 57.0(906) 
Total 100 (316) 100 (20) 100 (1255) 100(1591) 
 
 Table 6 shows the race distribution in the study population, all FDR-converter consisted 
of white, there is no Asian in New onsets.  
 
Table 6. Race Distribution for Entire Population 
Race New Onsets FDR-converters FDR-nonconverters Total 
 % (Counts) % (Counts) % (Counts) % (Counts) 
White  92.4 (292) 100 (20) 96.6 (1,192) 95.8(1504) 
Blcak 5.7 (18) 0(0) 2.8 (34) 3.3(52) 
Asian 0(0) 0(0) 0.3 (4) 0.3(4) 
Other* 1.9 (6) 0(0) 0.3 (4) 0.6(10) 
Total 100 (316) 100 (20) 100 (1234)** 100(1570) 
* Including multiple races 
** Frequency Missing = 21 
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 Table 7 shows the age distribution for the whole study population. There are 2 New 
Onset patients and 4 FDR-converters with ages greater than 20 years of age at the time of their 
first blood draws. 
Table 7. Age Distribution for Entire Population 
Age Mean Std Median Min. Max. 
New Onsets 9.4 4.38 10 1 31 
FDR-converter 14.3 11.47 10.5 2 41 
FDR-nonconverter 28.6 13.95 34 0 61 
                                        Std = standard deviation 
 
3.3 HLA-DQ SEROTYPE IN STUDY DATASET 
We classified HLA-serotype into four categories, X, DQ2, DQ8, and DQ2/DQ8. X indicates the 
participants’ HLA-serotype is neither DQ2 nor DQ8. DQ2, DQ8 indicates the people who only 
have either DQ2 or DQ8 serotype for their HLA. DQ2/DQ8 indicates the people have both DQ2 
and DQ8 serotype. The greatest risk of T1DM is found among the DQ2/DQ8individuals, 
followed by the DQ8 individuals then the DQ2 individuals and finally the lowest risk is X 
serotype. 
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Table 8. HLA-DQ Distribution for Subpopulation 
HLA-DQ Type New Onsets FDR-converters FDR-nonconverters Total 
 % (Counts) % (Counts) % (Counts) % (Counts) 
X 17.5 (51) 18.7 (3) 32.6 (399) 29.6 (453) 
DQ2 28.6 (83) 25.00 (4) 31.3 (383) 30.7 (470) 
DQ8 35.2 (102) 43.8 (7) 30.5 (374) 31.6 (483) 
DQ2/DQ8 18.7 (54) 12.50 (2) 5.6 (69) 8.1(125) 
Total 100 (290)* 100 (16)** 100 (1225)*** 100(1531) 
* Frequency Missing = 26 
** Frequency Missing = 4 
*** Frequency Missing = 30 
 
 
3.4 NUMBER OF POSITIVE ANTIGENS 
The number of positive antigens is one of the most important criteria in predicting T1DM. The 
recommended cutpoint for predicting T1DM is 4; in constrast <4 should predict no T1DM. 
3.4.1 Number of positive antigens in characteristics of subjects by subpopulation 
The number of positive antigens was assessed among three subpopulations: New onsets, FDR-
converters, and FDR-nonconverters. From Table 9, we found that new onsets group had a higher 
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number of positive antigens than FDR. The variance among FDR-converters is higher when 
compared with other two subpopulations. The FDR-converter group can be further divided into 
two subgroups by insulin start date. The FDR-converter who has a blood draw before starting 
insulin should have a similar number of positive antigens with the FDR-nonconverters. After 
using insulin, the FDR-converter would be expected to have similar number of positive antigens 
with the new onsets subjects. (Table 10) 
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Table 9.  Number of positive antigens in demographics by subpopulation 
Number 
of 
positive 
antigens 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Mean Std Median Q1 Q3 Mean Std Median Q1 Q3 
Gender 
8.6 2.8 10.0 9.0 10.0 2.8 4.3 0.0 0.0 8.0 0.9 2.5 0.0 0.0 0.0 Male 
Female 8.6 2.8 10.0 9.0 10.0 5.1 4.8 7.0 0.0 10.0 0.9 2.6 0.0 0.0 0.0 
Race 
8.6 2.7 10.0 9.0 10.0 4.3 4.7 0.0 0.0 10.0 0.9 2.5 0.0 0.0 0.0 White 
Black 8.3 3.3 10.0 9.0 10.0 . . . . . 1.5 3.2 0.0 0.0 0.0 
Asian . . . . . . . . . . 0.0 0.0 0.0 0.0 0.0 
Other 8.2 3.4 10.0 8.0 10.0 . . . . . 3.1 4.4 0.0 0.0 8.0 
HLA-DQ 
type 
8.7 2.8 10.0 9.0 10.0 4.6 5.0 4.0 0.0 9.5 0.9 2.6 0.0 0.0 0.0 X 
DQ2 8.5 2.9 10.0 8.0 10.0 1.0 3.0 0.0 0.0 0.0 0.8 2.4 0.0 0.0 0.0 
DQ8 8.3 3.0 10.0 8.0 10.0 5.7 4.6 8.0 0.0 10.0 1.0 2.7 0.0 0.0 0.0 
DQ2/DQ8 9.2 2.2 10.0 9.0 10.0 4.2 5.0 0.0 0.0 10.0 0.9 2.6 0.0 0.0 0.0 
All 8.6 2.8 10.0 9.0 10.0 4.3 4.7 0.0 0.0 10.0 0.9 2.5 0.0 0.0 0.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 10.  Number of positive antigens in demographics by subgroup of FDR-converter 
Number of positive antigens 
After insulin start Before insulin start 
Mean Std Median Q1 Q3 Mean Std Median Q1 Q3 
Gender 
6.8 4.3 9.0 3.0 10.0 1.5 3.6 0.0 0.0 0.0 Male 
Female 8.0 3.4 10.0 7.0 10.0 2.9 4.6 0.0 0.0 9.0 
Race 
7.7 3.6 10.0 7.0 10.0 2.4 4.2 0.0 0.0 1.0 White 
Black . . . . . . . . . . 
Asian . . . . . . . . . . 
Other . . . . . . . . . . 
HLA-DQ type 
9.3 1.0 9.5 8.5 10.0 0.0 0.0 0.0 0.0 0.0 X 
DQ2 3.3 5.8 0.0 0.0 10.0 0.1 0.4 0.0 0.0 0.0 
DQ8 8.1 3.1 10.0 7.0 10.0 3.3 4.8 0.0 0.0 9.5 
DQ2/DQ8 . . . . . 4.2 5.0 0.0 0.0 10.0 
All 7.7 3.6 10.0 7.0 10.0 2.4 4.2 0.0 0.0 1.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
 
Figure 5 and Figure 6 show the change in the number of positive antigens in three 
subpopulations over the follow up time. New onsets have the highest number of positive antigens 
and the FDR-nonconverters have the lowest number of positive antigens. The red line in Figure 5 
and Figure 6, represents FDR-converters before using insulin and FDR-converters after using 
insulin, respectively. Figure 5 and Figure 6 also show that before the FDR-converters started 
using insulin, their number of positive antigens had a lower value; but the number of positive 
antigens increases shortly after using insulin.   
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Figure 5. Comparison of number of positive antigens in New Onsets, FDR-converters before using insulin, 
and FDR-nonconverters over folloing time 
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Figure 6. Comparison of number of positive antigens in New Onsets, FDR-converters after using insulin, and FDR-
nonconverters over folloing time 
3.4.2 T1DM affected status by subpopulations 
According to the criterion, T1DM affected statuses were discriminated by four or more positive 
antigens, general affected status shown in Table 11. A p-value less than 0.0001 indicate that the 
affected status is significant among three subpopulations. 
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Table 11.  T1DM status by subpopulations 
Frequency 
Col Pct 
New Onsets FDR-converter FDR-nonconverter Total 
Affected 286 
91.4 
9 
45.0 
79 
6.3 
374 
Unaffected 27 
8.6 
11 
55.0 
1171 
93.7 
1209 
Total 313 20 1250 1583 
Frequency Missing = 8, P-value <0.0001 
 
From Figure 7, it can be seen that the new onsets have a relatively higher percentage for 
affect rates than FDR-nonconverters who tend to have a lower affect rates.  
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Figure 7. Percentage of T1DM affected in three subpopulations over time 
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3.5 TEN TEST ANTIGENS 
The ten test antigens are also important predictors of T1DM. The prior recommended cutoff for 
SI was 1.5 for all test antigens. For test antigens with SI >=1.5, the test result would be 
considered as positive. For test antigens with SI<1.5, the test result would consider as negative. 
A series of tables in Appendix B.1 shows the summary of SI of ten test antigens in 
characteristics of subjects by subpopulations. The new onsets have higher level of SI when 
compare with FDR. 
The series of figures in Appendix B.1.2 (P. 79) shows the change of ten test antigens’ SI 
over follow-up time by subpopulation. The SI in new onsets and FDR-nonconverters is relatively 
stable over time. New onsets and FDR-converters who used insulin had a higher SI level when 
compared with an FDR-converter who never used insulin, or an FDR-nonconverter. 
3.6 EVALUATION OF DIAGNOSIS TEST 
For the evaluation of the diagnostic test, we used the new onsets and the FDr-nonconverters. We 
included a total of 1,571 subjects for further evaluation. The blood test results were based on a 
subject’s first blood draw, which would provide a baseline performance of the diagnosis test. 
The ROC curve is a straightforward way to evaluate the diagnosis test. Two criteria were 
considered in this section to predict T1DM. 
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3.6.1 Criterion using test antigens 
Ten test antigens were measured based on their SI in blood draw test. From prior 
recommendations, 1.5 would be the cutoff to discriminate between a positive or negative antigen. 
For an SI>=1.5, the test result would be positive, whilst an SI<1.5, the test result would be 
deemed as being negative. According to this criterion, we created Table 12. Generally, the ten 
test antigens gave us good test results with high sensitivity and specificity. Based on the cutoff of 
1.5, we plotted the ROC curves for the ten test antigens. (Figure 8- Figure 17) The optimal 
cutpoint would be closer to the ideal point of (0, 1), which implies that the prediction of test 
antigens are good. 
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Table 12.  Effect of SI on predict T1DM* 
    2x2Table   Sensitivity Specificity 1-Specificity PPV NPV 
CNSA_EX2   A+ A-           
  Test + 251 55 80.2% 95.6% 4.4% 82.0% 95.1% 
  Test - 62 1195 
CNSA_MBP   A+ A-           
  Test + 255 56 81.5% 95.5% 4.5% 82.0% 95.4% 
  Test - 58 1194 
GLIA_GFAP   A+ A-           
  Test + 271 64 86.6% 94.9% 5.1% 80.9% 96.6% 
  Test - 42 1186 
GLIA_S100   A+ A-           
  Test + 265 70 84.7% 94.4% 5.6% 79.1% 96.1% 
  Test - 48 1180 
ISLA_Gad   A+ A-           
  Test + 279 79 89.1% 93.7% 6.3% 77.9% 97.2% 
  Test - 34 1171 
ISLA_Gad55   A+ A-           
  Test + 278 74 88.8% 94.1% 5.9% 79.0% 97.1% 
  Test - 35 1176 
ISLA_PI   A+ A-           
  Test + 284 102 90.7% 91.8% 8.2% 73.6% 97.5% 
  Test - 29 1148 
ISLA_Tep69   A+ A-           
  Test + 281 90 89.8% 92.8% 7.2% 75.7% 97.3% 
  Test - 32 1160 
MIP_Abbos   A+ A-           
  Test + 285 83 91.1% 93.4% 6.6% 77.4% 97.7% 
  Test - 28 1167 
MIP_BSA   A+ A-           
  Test + 287 88 91.7% 93.0% 7.0% 76.5% 97.8% 
  Test - 26 1162 
*A+ =New Onsets, A- =FDR-nonconverter 
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Figure 8. ROC curve for CNSA_EX2  
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Figure 9. ROC curve for CNSA_MBP  
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Figure 10. ROC curve for GLIA_GFAP  
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Figure 11. ROC curve for GLIA_S100 
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Figure 12. ROC curve for ISLA_Gad 
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Figure 13. ROC curve for ISLA_Gad55 
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Figure 14. ROC curve for ISLA_PI 
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Figure 15. ROC curve for ISLA_Tep69  
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Figure 16. ROC curve for MIP_Abbos 
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Figure 17. ROC curve for MIP_BSA  
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Table 13, Table 14 and Figure 18 indicate that 1.5 is a good cutoff because of the higher 
value of AUC and ranges from 0.9244 to 0.930 for these test antigens. 
 
Table 13.  AUC for 10 test antigens and chance* 
ROC Association Statistics 
ROC Model Mann-Whitney Somers' D 
(Gini) 
Gamma Tau-a 
Area Standard 
Error 
95% Wald 
Confidence Limits 
CNSA_EX2 0.9256 0.0104 0.9052 0.9460 0.8513 0.8513 0.2728 
CNSA_MBP 0.9244 0.0106 0.9036 0.9452 0.8488 0.8488 0.2720 
GLIA_GFAP 0.9309 0.0103 0.9107 0.9512 0.8618 0.8618 0.2762 
GLIA_S100 0.9252 0.0108 0.9040 0.9465 0.8505 0.8505 0.2726 
ISLA_Gad 0.9363 0.00974 0.9172 0.9554 0.8726 0.8726 0.2797 
ISLA_Gad55 0.9425 0.00846 0.9260 0.9591 0.8851 0.8851 0.2837 
ISLA_PI 0.9330 0.00914 0.9151 0.9509 0.8661 0.8661 0.2776 
ISLA_Tep69 0.9347 0.00976 0.9155 0.9538 0.8693 0.8693 0.2786 
MIP_Abbos 0.9402 0.00943 0.9218 0.9587 0.8805 0.8805 0.2822 
MIP_BSA 0.9430 0.00892 0.9255 0.9605 0.8859 0.8859 0.2840 
Chance 0.5000 0 0.5000 0.5000 0 . 0 
*Chance represents the diagonal line without predictive value 
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Table 14.  AUC comparison between 10 test antigens and chance* 
ROC Contrast Estimation and Testing Results by Row 
Contrast Estimate Standard 
Error 
95% Wald 
Confidence Limits 
Chi-Square Pr > ChiSq 
CNSA_EX2 - Chance 0.4256 0.0104 0.4052 0.4460 1669.8120 <.0001 
CNSA_MBP - Chance 0.4244 0.0106 0.4036 0.4452 1598.0204 <.0001 
GLIA_GFAP - Chance 0.4309 0.0103 0.4107 0.4512 1740.7075 <.0001 
GLIA_S100 - Chance 0.4252 0.0108 0.4040 0.4465 1537.2854 <.0001 
ISLA_Gad - Chance 0.4363 0.00974 0.4172 0.4554 2007.7545 <.0001 
ISLA_Gad55 - Chance 0.4425 0.00846 0.4260 0.4591 2738.5590 <.0001 
ISLA_PI - Chance 0.4330 0.00914 0.4151 0.4509 2243.2769 <.0001 
ISLA_Tep69 - Chance 0.4347 0.00976 0.4155 0.4538 1982.7429 <.0001 
MIP_Abbos - Chance 0.4402 0.00943 0.4218 0.4587 2180.8534 <.0001 
MIP_BSA - Chance 0.4430 0.00892 0.4255 0.4605 2465.5871 <.0001 
*Chance represents the diagonal line without predictive value 
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Figure 18. ROC curve for 10 test antigens and chance line  
3.6.2 Criterion using number of test antigens 
The numbers of positive results from the ten test antigens were counted for predicting the T1DM. 
The recommendation cutoff of four was adopted. The prediction at this cutoff seems good 
according to Figure 19. 
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Figure 19. ROC curve for number of positive antigens under the cutoff= 4 
3.6.3 Alternative cutoff for diagnosis test 
Usually, when the cutoff is decided, a Student’s T-test can be used to measure the effect of the 
diagnosis test. From Table 15 and Table 16, it is clear that the mean of SI among new onsets is 
significantly higher than that of FDR-nonconverters. However, we want to know how well the 
cutoff of 1.5 performed. It is still interesting to determine whether 1.5 is too strict or too loose for 
prediction. One method of analysis is the sensitivity and specificity at several cut points.   
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Table 15.  Mean of SI between New onsets and FDR-converters 
 New Onsets(N=316) FDR-nonconverter(n=1,255) p-value* 
CNSA_EX2si 1.83 1.10 <.0001 
CNSA_MBPsi 1.79 1.11 <.0001 
GLIA_GFAPsi 1.91 1.13 <.0001 
GLIA_S100si 1.91 1.12 <.0001 
ISLA_Gadsi 2.03 1.13 <.0001 
ISLA_Gad55si 2.04 1.13 <.0001 
ISLA_PIsi 2.10 1.17 <.0001 
ISLA_Tep69si 2.12 1.14 <.0001 
MIP_Abbossi 2.14 1.14 <.0001 
MIP_BSAsi 2.18 1.14 <.0001 
*The mean were compared using Student’s t-test for unequal variance.  
Table 16.  Mean of SI between New onsets and FDR-converters 
 New Onsets(N=313) FDR-nonconverter(n=1,250) p-value* 
Number of positive antigens 8.7 0.6 <.0001 
 
Using 4 as the cutoff criterion for the number of positive antigens, we built a pair 
comparison table (Table 17) with corresponding ROC curves (Figure 20). It was hypothesized 
that 5 or 6 would be a better cutoff to predict the T1DM due to a better trade-off between 
sensitivity and specificity. 
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Table 17.  Statistical output of number of positive antigens for new onsets 
Obs CUTOFF COUNT PERCENT PCT_ROW TP_RATE FP_RATE 
1 0 155 9.86633 34.9887 91.1392 12.3506 
2 1 99 6.30172 25.7143 90.5063 7.8884 
3 2 88 5.60153 23.5294 90.5063 7.0120 
4 3 79 5.02864 21.6438 90.5063 6.2948 
5 4 74 4.71038 20.7283 89.5570 5.8964 
6 5 67 4.26480 19.1429 89.5570 5.3386 
7 6 61 3.88288 17.8886 88.6076 4.8606 
8 7 57 3.62826 17.3780 85.7595 4.5418 
9 8 47 2.99173 15.6146 80.3797 3.7450 
10 9 34 2.16423 13.4387 69.3038 2.7092 
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Figure 20. Optimal points in ROC curve under different cutoff of  number of positive antigens  
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Using 1.5 as the cutoff criterion for the 10 test antigens, Appendix B.1.3 (Page 90) 
indicates the optimal cutoff would be a little lower than 1.5, and ranges from 1.25-1.50. 
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4.0  CONCLUSION 
The data cleaning process is one of the most important steps in the data analysis, and it helps us 
to avoid false conclusions and misdirected investigations using incorrect or inconsistent data.  
Based on previous data, a number of hand calculations were involved. Thus, data cleaning is 
necessary in this setting. Despite the existence of a few mistakes, the accuracy of the hand 
calculations was quite good, and the error rate was less than 1%. However, a high quality data 
analysis has zero tolerance for mistakes and it reminds us of the importance of data checking and 
cleaning prior to analysis.  
My thesis is a first look at the SI values and number of positive antigens in new onsets, 
FDR-converters, and FDR-nonconverters from this longitudinal study of juvenile onset diabetics 
and their family members. Preliminary summary was performed to generate information in the 
various subpopulations. The value of SI is stable in new onsets and FDR-nonconverters. The SI 
in new onsets has higher values than that of FDRs. The SI values in FDR-converters are higher 
than that of FDR-nonconveters. When we consider two subgroups among the FDR-converters 
based on the start of insulin, the SI values in FDR-converters before the start of insulin have 
similar values (<1.5) to that of FDR-nonconveters; the SI values in FDR-converters after insulin 
start have similar values (>=1.5) with that found in new onsets.  
The number of positive antigens in three subpopulations also has consistency similar to 
the SI values. The number of positive antigens is stable in new onsets and FDR-nonconverters, 
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where new onsets have higher values and FDR-nonconverters have lower values. After 
considering the subgroups in the FDR-converters by their insulin start date, the number of 
positive antigens in FDR-converters before the start of insulin have similar values (<4) compared 
with FDR-nonconverters; and, the number of positive antigens in FDR-converters after the start 
of insulin  have similar values (>=4) found in the new onsets. 
The evaluation of a diagnostic test is an exploratory part of this thesis. ROC curves are 
frequently used to evaluate diagnostic tests to differentiate “healthy” individuals from “diseased” 
individuals or predict the existence of disease. We applied ROC analysis curves to evaluate the 
two criteria of T1DM prediction. The overall performance of two criteria is excellent. This 
indicates that the prior cutpoint recommendations for these diagnostic tests work well. However, 
it is necessary to explore the optimal cutoff for these two criteria for our cohort. 
We found evidence to suggest that: 
• For the SI, 1.5 is a good cutoff with high AUC. However, after careful 
examination of the previous cutoff comparison for the 10 test antigens, a slightly 
lower cutoff value may provide a more optimal tradeoff for the diagnostic test, i.e. 
using an SI cutoff of (1.25-1.5). 
• For the number of positive antigens, 4 is a good cutoff for discrimination of 
T1DM. However, there is suggestion that a slightly higher value may provide a 
more optimal tradeoff for the diagnostic test, i.e. 5 or 6.  
Before changes are implemented further analytical work needs to be performed. Most 
importantly, this should include the identification and inclusion of a greater number of FDR-
converters and their respective antigen test results. 
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In conclusion, the development of a better understanding of the pattern of T-cell response 
among diabetes and non-diabetic children, and those progressing to diabetes may give us tools to 
predict the early onset of disease. It is this point in time where therapeutic intervention could be 
focused to help stem the development of T1DM or to dramatically reduces its severity. Focusing 
on prevention and/or attenuating progression is the public health approach to the treatment of 
disease. 
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APPENDIX A 
APPENDIX FOR DATA CLEANING 
Table 18.  Both Well1 and Well2 Missing Observations List 
PID BloodDrawDate PID BloodDrawDate 
116 2-May-07 48830103 21-Aug-06 
204 28-Aug-07 49020101 12-Feb-07 
226 23-Oct-07 49180101 8-Aug-07 
233 11-Jun-07 49900103 12-Feb-07 
27240101 13-Feb-06 49900104 12-Feb-07 
29200104 31-Mar-05 70820103 30-Nov-05 
32170101 9-May-07 70870101 4-Apr-07 
36420102 31-Mar-08 71110103 31-Dec-05 
40080102 12-Feb-07 71540101 12-Feb-07 
40690101 4-Feb-06 71630103 25-Jul-07 
43320103 30-Dec-05 71640103 18-Sep-06 
43320106 30-Dec-05 71700104 12-Feb-07 
45750102 12-Feb-07 71720103 24-Mar-08 
45920102 26-Sep-07 71890101 14-Mar-07 
47330104 4-Feb-04 71960103 10-Jul-06 
48830103 18-May-06   
 
54 
Table 19.  Miscalculated WELLMEAN Observations List 
PID BloodDrawDate 
38700101 26-Sep-05 
40840101 25-Mar-08 
47800101 26-Sep-05 
48510106 27-Jul-05 
48920101 10-Sep-05 
70600105 29-Jul-05 
 
 
Table 20.  Miscalculated SI Observations List 
PID BloodDrawDate PID BloodDrawDate 
186 23-Jan-07 48790103 25-Mar-06 
254 24-Jul-07 48920101 10-Sep-05 
256 24-Jul-07 48950102 27-Oct-07 
258 24-Jul-07 49090103 9-Oct-06 
35270104 1-Apr-06 49110104 13-Feb-06 
38700101 26-Sep-05 49300101 13-Feb-06 
39730204 9-Jul-07 49400105 28-Apr-08 
40660102 27-Oct-07 49410101 13-Feb-06 
43330102 21-Oct-06 49650103 10-Jul-06 
46390101 25-Jul-07 49910103 15-Feb-06 
47800101 26-Sep-05 70600105 29-Jul-05 
47980101 22-Jan-07 71030101 24-Jul-07 
47980104 25-Jul-07 71390101 15-Feb-06 
48510106 27-Jul-05 71390103 15-Feb-06 
48660101 6-Jun-07   
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Table 21.  False-negative results: SI>1.5 with “Negative” result 
PID FID BloodDrawDate Analyte 
48790103 4879 25-Mar-06 CNSA_MBP 
254 10186 24-Jul-07 GLIA_GFAP 
48920101 4892 10-Sep-05 ISLA_PI 
48920101 4892 10-Sep-05 ISLA_Tep69 
48920101 4892 10-Sep-05 MIP_Abbos 
48920101 4892 10-Sep-05 MIP_BSA 
 
Table 22.  False-positive results: Si<1.5 with “Positive” result 
PID FID BloodDrawDate Analyte 
49400105 4940 28-Apr-08 CNSA_EX2 
49400105 4940 28-Apr-08 CNSA_MBP 
49400105 4940 28-Apr-08 GLIA_GFAP 
49400105 4940 28-Apr-08 GLIA_S100 
49400105 4940 28-Apr-08 ISLA_Gad 
49400105 4940 28-Apr-08 ISLA_Gad55 
42280101 4228 7-Nov-07 ISLA_PI 
49400105 4940 28-Apr-08 ISLA_PI 
39730204 3973 9-Jul-07 ISLA_Tep69 
49400105 4940 28-Apr-08 ISLA_Tep69 
71030101 7103 24-Jul-07 ISLA_Tep69 
39730204 3973 9-Jul-07 MIP_Abbos 
49400105 4940 28-Apr-08 MIP_Abbos 
49400105 4940 28-Apr-08 MIP_BSA 
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Table 23.  False-unaffected interpretations: number of positive test antigens >4, but interpreted as “Unaffected”. 
PID FID BloodDrawDate 
32960101 3296 21-Apr-08 
36569899 3656 5-Dec-05 
40410104 4041 20-Jun-05 
40660102 4066 10-Oct-05 
41700101 4170 14-Nov-05 
44520102 4452 16-Aug-07 
44580102 4458 2-Jul-07 
46570101 4657 5-Dec-05 
47280101 4728 18-Apr-05 
47930101 4793 16-Aug-07 
48460103 4846 5-Nov-05 
48890102 4889 28-Mar-07 
48920101 4892 10-Sep-05 
49010103 4901 14-Jun-06 
49420203 4942 10-Jan-07 
71230101 7123 20-Jan-07 
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Table 24.  False-affected interpretations: number of positive test antigens <4, but interpreted as “Affected”. PID FID BloodDrawDate 
46420101 4642 25-Mar-08 
48910103 4891 21-Sep-06 
49400105 4940 28-Apr-08 
71770204 7177 5-Aug-06 
71830103 7183 30-Sep-06 
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APPENDIX B 
APPENDIX FOR PRELIMINARY SUMMARY AND DIAGNOSTIC TEST 
EVALUATION 
B.1 SI OF TEN TEST ANTIGENS  
B.1.1 SI of ten test antigens in demographics by subpopulation 
Following 20 tables shows the SI in ten test antigens stratified by the demographics and 
subpopulation.
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Table 25. SI of CNSA_EX2 in demographics before insulin start 
CNSA_EX2si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.8 0.4 1.8 1.5 2.0 0.8 4.0 1.1 0.2 1.0 1.0 1.1 0.9 1.6 1.1 0.2 1.1 1.0 1.1 0.6 2.8 Male 
Female 1.8 0.7 1.8 1.5 2.0 0.9 12.4 1.3 0.4 1.1 1.0 1.7 1.0 2.2 1.1 0.2 1.1 1.0 1.1 0.7 2.8 
Race 
1.8 0.6 1.8 1.5 2.0 0.8 12.4 1.2 0.4 1.1 1.0 1.2 0.9 2.2 1.1 0.2 1.1 1.0 1.1 0.6 2.8 White 
Black 1.8 0.5 1.7 1.5 2.0 1.0 3.3 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.9 1.8 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 1.8 0.6 1.6 1.4 2.1 1.1 3.1 . . . . . . . 1.3 0.4 1.1 1.1 1.5 0.9 2.2 
HLA-DQ type 
1.8 0.4 1.7 1.6 2.0 0.9 3.0 1.0 0.1 1.0 1.0 1.1 1.0 1.2 1.1 0.2 1.1 1.0 1.1 0.7 2.8 X 
DQ2 1.8 0.8 1.8 1.5 2.0 0.8 12.4 1.0 0.1 1.1 1.0 1.1 0.9 1.1 1.1 0.2 1.1 1.0 1.1 0.7 2.5 
DQ8 1.8 0.5 1.7 1.5 2.0 0.8 4.0 1.3 0.4 1.1 1.1 1.5 1.0 2.2 1.1 0.2 1.1 1.0 1.1 0.6 2.5 
DQ2/DQ8 1.9 0.4 1.8 1.6 2.0 0.9 3.5 1.3 0.5 1.1 1.0 1.7 0.9 2.1 1.1 0.2 1.1 1.0 1.1 0.8 2.2 
All 1.8 0.6 1.8 1.5 2.0 0.8 12.4 1.2 0.4 1.1 1.0 1.2 0.9 2.2 1.1 0.2 1.1 1.0 1.1 0.6 2.8 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 26. SI of CNSA_EX2 in demographics after insulin start 
CNSA_EX2si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.8 0.4 1.8 1.5 2.0 0.8 4.0 1.6 0.5 1.6 1.1 1.8 1.1 2.5 1.1 0.2 1.1 1.0 1.1 0.6 2.8 Male 
Female 1.8 0.7 1.8 1.5 2.0 0.9 12.4 1.8 0.5 1.7 1.5 2.1 1.0 2.9 1.1 0.2 1.1 1.0 1.1 0.7 2.8 
Race 
1.8 0.6 1.8 1.5 2.0 0.8 12.4 1.7 0.5 1.6 1.5 2.0 1.0 2.9 1.1 0.2 1.1 1.0 1.1 0.6 2.8 White 
Black 1.8 0.5 1.7 1.5 2.0 1.0 3.3 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.9 1.8 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 1.8 0.6 1.6 1.4 2.1 1.1 3.1 . . . . . . . 1.3 0.4 1.1 1.1 1.5 0.9 2.2 
HLA-DQ type 
1.8 0.4 1.7 1.6 2.0 0.9 3.0 1.9 0.3 1.7 1.7 2.0 1.6 2.3 1.1 0.2 1.1 1.0 1.1 0.7 2.8 X 
DQ2 1.8 0.8 1.8 1.5 2.0 0.8 12.4 1.3 0.4 1.1 1.0 1.8 1.0 1.8 1.1 0.2 1.1 1.0 1.1 0.7 2.5 
DQ8 1.8 0.5 1.7 1.5 2.0 0.8 4.0 1.8 0.5 1.6 1.5 2.1 1.1 2.9 1.1 0.2 1.1 1.0 1.1 0.6 2.5 
DQ2/DQ8 1.9 0.4 1.8 1.6 2.0 0.9 3.5 . . . . . . . 1.1 0.2 1.1 1.0 1.1 0.8 2.2 
All 1.8 0.6 1.8 1.5 2.0 0.8 12.4 1.7 0.5 1.6 1.5 2.0 1.0 2.9 1.1 0.2 1.1 1.0 1.1 0.6 2.8 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 27. SI of CNSA_MBP in demographics before insulin start 
CNSA_MBPsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.8 0.4 1.7 1.5 2.0 0.8 3.9 1.1 0.2 1.1 1.0 1.1 0.9 1.8 1.1 0.2 1.1 1.0 1.1 0.7 3.2 Male 
Female 1.8 0.5 1.8 1.5 2.0 0.9 3.3 1.3 0.4 1.1 1.0 1.7 1.0 2.3 1.1 0.3 1.1 1.0 1.1 0.5 9.0 
Race 
1.8 0.4 1.8 1.5 2.0 0.8 3.9 1.3 0.4 1.1 1.0 1.3 0.9 2.3 1.1 0.3 1.1 1.0 1.1 0.5 9.0 White 
Black 1.8 0.5 1.7 1.5 2.0 0.9 3.3 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.7 2.2 
Asian . . . . . . . . . . . . . . 1.1 0.2 1.1 1.0 1.2 1.0 1.2 
Other 1.8 0.7 1.7 1.5 2.2 1.0 3.2 . . . . . . . 1.3 0.4 1.1 1.0 1.4 1.0 2.3 
HLA-DQ type 
1.8 0.4 1.8 1.5 2.0 0.9 3.1 1.1 0.1 1.0 1.0 1.1 1.0 1.2 1.1 0.3 1.1 1.0 1.1 0.5 9.0 X 
DQ2 1.8 0.5 1.7 1.5 2.0 0.8 3.6 1.0 0.1 1.1 1.0 1.1 0.9 1.2 1.1 0.2 1.1 1.0 1.1 0.6 2.8 
DQ8 1.8 0.5 1.7 1.5 2.0 0.9 3.9 1.3 0.4 1.1 1.0 1.6 1.0 2.3 1.1 0.3 1.1 1.0 1.1 0.6 6.0 
DQ2/DQ8 1.9 0.4 1.8 1.6 2.1 0.9 3.2 1.4 0.5 1.3 1.1 1.8 1.0 2.1 1.1 0.3 1.1 1.0 1.1 0.8 3.2 
All 1.8 0.4 1.8 1.5 2.0 0.8 3.9 1.3 0.4 1.1 1.0 1.3 0.9 2.3 1.1 0.3 1.1 1.0 1.1 0.5 9.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 28. SI of CNSA_MBP in demographics after insulin start 
CNSA_MBPsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.8 0.4 1.7 1.5 2.0 0.8 3.9 1.6 0.6 1.6 1.2 1.8 1.0 2.6 1.1 0.2 1.1 1.0 1.1 0.7 3.2 Male 
Female 1.8 0.5 1.8 1.5 2.0 0.9 3.3 1.7 0.5 1.6 1.5 1.9 1.1 2.8 1.1 0.3 1.1 1.0 1.1 0.5 9.0 
Race 
1.8 0.4 1.8 1.5 2.0 0.8 3.9 1.7 0.5 1.6 1.5 1.9 1.0 2.8 1.1 0.3 1.1 1.0 1.1 0.5 9.0 White 
Black 1.8 0.5 1.7 1.5 2.0 0.9 3.3 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.7 2.2 
Asian . . . . . . . . . . . . . . 1.1 0.2 1.1 1.0 1.2 1.0 1.2 
Other 1.8 0.7 1.7 1.5 2.2 1.0 3.2 . . . . . . . 1.3 0.4 1.1 1.0 1.4 1.0 2.3 
HLA-DQ type 
1.8 0.4 1.8 1.5 2.0 0.9 3.1 1.8 0.3 1.7 1.6 2.1 1.5 2.3 1.1 0.3 1.1 1.0 1.1 0.5 9.0 X 
DQ2 1.8 0.5 1.7 1.5 2.0 0.8 3.6 1.3 0.4 1.1 1.0 1.7 1.0 1.7 1.1 0.2 1.1 1.0 1.1 0.6 2.8 
DQ8 1.8 0.5 1.7 1.5 2.0 0.9 3.9 1.8 0.5 1.6 1.5 1.9 1.1 2.8 1.1 0.3 1.1 1.0 1.1 0.6 6.0 
DQ2/DQ8 1.9 0.4 1.8 1.6 2.1 0.9 3.2 . . . . . . . 1.1 0.3 1.1 1.0 1.1 0.8 3.2 
All 1.8 0.4 1.8 1.5 2.0 0.8 3.9 1.7 0.5 1.6 1.5 1.9 1.0 2.8 1.1 0.3 1.1 1.0 1.1 0.5 9.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 29. SI of  GLIA_GFAP in demographics before insulin start 
GLIA_GFAPsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.9 0.5 1.9 1.6 2.2 0.9 3.9 1.2 0.5 1.0 0.9 1.2 0.9 2.6 1.1 0.3 1.1 1.0 1.2 0.5 3.0 Male 
Female 1.9 0.5 1.8 1.6 2.1 0.5 3.6 1.4 0.5 1.1 1.0 1.7 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.6 23.1 
Race 
1.9 0.5 1.9 1.6 2.2 0.5 3.9 1.3 0.5 1.1 1.0 1.3 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.5 23.1 White 
Black 1.9 0.5 1.8 1.6 2.1 1.0 3.1 . . . . . . . 1.1 0.3 1.1 1.0 1.1 0.8 1.9 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.0 0.6 1.8 1.6 2.6 1.1 3.0 . . . . . . . 1.3 0.3 1.2 1.0 1.6 1.0 1.9 
HLA-DQ type 
1.9 0.4 1.9 1.7 2.1 0.9 3.4 1.1 0.1 1.1 1.1 1.2 1.0 1.3 1.1 0.3 1.1 1.0 1.2 0.7 3.5 X 
DQ2 1.9 0.5 1.9 1.6 2.2 0.9 3.6 1.1 0.2 1.0 1.0 1.1 0.9 1.4 1.1 0.3 1.1 1.0 1.1 0.6 3.0 
DQ8 1.9 0.5 1.8 1.6 2.2 0.9 3.9 1.4 0.6 1.1 1.0 1.7 0.9 2.6 1.2 0.7 1.1 1.0 1.2 0.5 23.1 
DQ2/DQ8 2.0 0.5 1.9 1.7 2.2 0.5 3.6 1.5 0.7 1.1 1.1 1.9 0.9 2.7 1.1 0.2 1.1 1.0 1.2 0.7 2.3 
All 1.9 0.5 1.9 1.6 2.2 0.5 3.9 1.3 0.5 1.1 1.0 1.3 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.5 23.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 30. SI of  GLIA_GFAP in demographics after insulin start 
GLIA_GFAPsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.9 0.5 1.9 1.6 2.2 0.9 3.9 1.7 0.7 1.6 1.1 2.5 1.0 2.6 1.1 0.3 1.1 1.0 1.2 0.5 3.0 Male 
Female 1.9 0.5 1.8 1.6 2.1 0.5 3.6 1.9 0.4 1.9 1.6 2.2 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.6 23.1 
Race 
1.9 0.5 1.9 1.6 2.2 0.5 3.9 1.8 0.5 1.9 1.4 2.2 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.5 23.1 White 
Black 1.9 0.5 1.8 1.6 2.1 1.0 3.1 . . . . . . . 1.1 0.3 1.1 1.0 1.1 0.8 1.9 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.0 0.6 1.8 1.6 2.6 1.1 3.0 . . . . . . . 1.3 0.3 1.2 1.0 1.6 1.0 1.9 
HLA-DQ type 
1.9 0.4 1.9 1.7 2.1 0.9 3.4 1.7 0.4 1.8 1.4 1.9 1.0 1.9 1.1 0.3 1.1 1.0 1.2 0.7 3.5 X 
DQ2 1.9 0.5 1.9 1.6 2.2 0.9 3.6 1.5 0.5 1.4 1.1 2.0 1.1 2.0 1.1 0.3 1.1 1.0 1.1 0.6 3.0 
DQ8 1.9 0.5 1.8 1.6 2.2 0.9 3.9 1.9 0.5 2.1 1.6 2.3 0.9 2.7 1.2 0.7 1.1 1.0 1.2 0.5 23.1 
DQ2/DQ8 2.0 0.5 1.9 1.7 2.2 0.5 3.6 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.7 2.3 
All 1.9 0.5 1.9 1.6 2.2 0.5 3.9 1.8 0.5 1.9 1.4 2.2 0.9 2.7 1.1 0.5 1.1 1.0 1.2 0.5 23.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 31. SI of GLIA_S100 in demographics before insulin start 
GLIA_S100si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.2 0.4 1.1 1.0 1.1 0.8 2.3 1.1 0.3 1.1 1.0 1.2 0.5 2.9 Male 
Female 1.9 0.5 1.9 1.6 2.2 0.9 3.8 1.4 0.5 1.1 1.0 1.7 0.9 2.6 1.1 0.3 1.1 1.0 1.2 0.4 5.9 
Race 
1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.3 0.5 1.1 1.0 1.3 0.8 2.6 1.1 0.3 1.1 1.0 1.2 0.4 5.9 White 
Black 1.9 0.5 1.8 1.6 2.2 1.0 3.1 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 2.1 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 2.0 0.6 1.8 1.5 2.6 1.0 3.1 . . . . . . . 1.3 0.3 1.1 1.0 1.5 0.9 1.9 
HLA-DQ type 
1.9 0.4 1.9 1.7 2.2 0.9 3.0 1.1 0.1 1.0 1.0 1.2 1.0 1.2 1.1 0.3 1.1 1.0 1.2 0.5 3.5 X 
DQ2 1.9 0.5 1.9 1.6 2.2 0.7 3.7 1.1 0.1 1.1 1.0 1.1 0.8 1.3 1.1 0.3 1.1 1.0 1.1 0.6 5.9 
DQ8 1.9 0.5 1.8 1.6 2.2 0.9 4.1 1.4 0.6 1.1 1.0 2.0 0.9 2.4 1.1 0.3 1.1 1.0 1.2 0.4 2.9 
DQ2/DQ8 2.0 0.5 1.9 1.7 2.2 1.0 3.8 1.5 0.6 1.1 1.1 2.0 1.0 2.6 1.1 0.2 1.1 1.0 1.2 0.8 2.4 
All 1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.3 0.5 1.1 1.0 1.3 0.8 2.6 1.1 0.3 1.1 1.0 1.2 0.4 5.9 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 32. SI of GLIA_S100 in demographics after insulin start 
GLIA_S100si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.9 0.7 1.8 1.2 2.3 1.1 3.1 1.1 0.3 1.1 1.0 1.2 0.5 2.9 Male 
Female 1.9 0.5 1.9 1.6 2.2 0.9 3.8 1.8 0.5 1.7 1.4 2.2 1.0 2.6 1.1 0.3 1.1 1.0 1.2 0.4 5.9 
Race 
1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.8 0.5 1.7 1.4 2.2 1.0 3.1 1.1 0.3 1.1 1.0 1.2 0.4 5.9 White 
Black 1.9 0.5 1.8 1.6 2.2 1.0 3.1 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 2.1 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 2.0 0.6 1.8 1.5 2.6 1.0 3.1 . . . . . . . 1.3 0.3 1.1 1.0 1.5 0.9 1.9 
HLA-DQ type 
1.9 0.4 1.9 1.7 2.2 0.9 3.0 1.6 0.2 1.6 1.5 1.8 1.4 1.9 1.1 0.3 1.1 1.0 1.2 0.5 3.5 X 
DQ2 1.9 0.5 1.9 1.6 2.2 0.7 3.7 1.5 0.4 1.3 1.1 1.9 1.1 1.9 1.1 0.3 1.1 1.0 1.1 0.6 5.9 
DQ8 1.9 0.5 1.8 1.6 2.2 0.9 4.1 1.9 0.6 2.0 1.6 2.3 1.0 3.1 1.1 0.3 1.1 1.0 1.2 0.4 2.9 
DQ2/DQ8 2.0 0.5 1.9 1.7 2.2 1.0 3.8 . . . . . . . 1.1 0.2 1.1 1.0 1.2 0.8 2.4 
All 1.9 0.5 1.9 1.6 2.2 0.7 4.1 1.8 0.5 1.7 1.4 2.2 1.0 3.1 1.1 0.3 1.1 1.0 1.2 0.4 5.9 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 33. SI of ISLA_Gad in demographics before insulin start 
ISLA_Gadsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.3 0.5 1.1 1.0 1.2 0.9 2.5 1.2 0.3 1.1 1.0 1.2 0.5 6.3 Male 
Female 2.0 0.5 2.0 1.7 2.3 0.9 4.0 1.4 0.5 1.1 1.0 1.8 0.9 2.7 1.1 0.3 1.1 1.0 1.2 0.5 5.7 
Race 
2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.3 0.5 1.1 1.0 1.5 0.9 2.7 1.1 0.3 1.1 1.0 1.2 0.5 6.3 White 
Black 2.0 0.5 2.0 1.7 2.3 1.0 3.0 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 2.2 
Asian . . . . . . . . . . . . . . 1.0 0.1 1.0 0.9 1.1 0.9 1.1 
Other 2.1 0.7 2.0 1.6 2.9 0.9 3.5 . . . . . . . 1.4 0.4 1.2 1.1 1.8 0.9 1.9 
HLA-DQ type 
2.0 0.4 2.0 1.7 2.2 0.9 3.3 1.1 0.2 1.1 0.9 1.2 0.9 1.2 1.1 0.3 1.1 1.0 1.2 0.5 3.2 X 
DQ2 2.0 0.5 1.9 1.7 2.3 0.8 3.7 1.1 0.2 1.1 1.0 1.2 0.9 1.5 1.1 0.3 1.1 1.0 1.1 0.6 3.8 
DQ8 2.0 0.6 2.0 1.6 2.3 0.8 4.7 1.4 0.6 1.1 1.0 2.0 1.0 2.5 1.2 0.4 1.1 1.0 1.2 0.5 6.3 
DQ2/DQ8 2.1 0.5 2.1 1.8 2.4 0.9 3.8 1.6 0.6 1.5 1.1 2.0 0.9 2.7 1.1 0.3 1.1 1.0 1.2 0.7 2.8 
All 2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.3 0.5 1.1 1.0 1.5 0.9 2.7 1.2 0.3 1.1 1.0 1.2 0.5 6.3 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 34. SI of ISLA_Gad in demographics after insulin start 
ISLA_Gadsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.9 0.8 1.8 1.4 2.5 1.1 3.0 1.2 0.3 1.1 1.0 1.2 0.5 6.3 Male 
Female 2.0 0.5 2.0 1.7 2.3 0.9 4.0 1.9 0.6 2.0 1.5 2.4 1.1 3.0 1.1 0.3 1.1 1.0 1.2 0.5 5.7 
Race 
2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.9 0.6 2.0 1.4 2.4 1.1 3.0 1.1 0.3 1.1 1.0 1.2 0.5 6.3 White 
Black 2.0 0.5 2.0 1.7 2.3 1.0 3.0 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 2.2 
Asian . . . . . . . . . . . . . . 1.0 0.1 1.0 0.9 1.1 0.9 1.1 
Other 2.1 0.7 2.0 1.6 2.9 0.9 3.5 . . . . . . . 1.4 0.4 1.2 1.1 1.8 0.9 1.9 
HLA-DQ type 
2.0 0.4 2.0 1.7 2.2 0.9 3.3 1.7 0.3 1.6 1.5 1.8 1.4 2.0 1.1 0.3 1.1 1.0 1.2 0.5 3.2 X 
DQ2 2.0 0.5 1.9 1.7 2.3 0.8 3.7 1.4 0.6 1.1 1.1 2.1 1.1 2.1 1.1 0.3 1.1 1.0 1.1 0.6 3.8 
DQ8 2.0 0.6 2.0 1.6 2.3 0.8 4.7 2.1 0.6 2.2 1.5 2.5 1.1 3.0 1.2 0.4 1.1 1.0 1.2 0.5 6.3 
DQ2/DQ8 2.1 0.5 2.1 1.8 2.4 0.9 3.8 . . . . . . . 1.1 0.3 1.1 1.0 1.2 0.7 2.8 
All 2.0 0.5 2.0 1.7 2.3 0.8 4.7 1.9 0.6 2.0 1.4 2.4 1.1 3.0 1.2 0.3 1.1 1.0 1.2 0.5 6.3 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 35. SI of ISLA_Gad55 in demographics before insulin start 
ISLA_Gad55si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.0 0.5 2.0 1.7 2.3 0.8 3.8 1.2 0.4 1.1 1.0 1.2 0.9 2.3 1.2 0.3 1.1 1.0 1.2 0.6 3.1 Male 
Female 2.0 0.5 2.0 1.7 2.3 0.9 4.2 1.4 0.5 1.1 1.1 1.6 0.9 2.8 1.2 0.3 1.1 1.0 1.2 0.5 3.6 
Race 
2.0 0.5 2.0 1.7 2.3 0.8 4.2 1.3 0.5 1.1 1.0 1.5 0.9 2.8 1.2 0.3 1.1 1.0 1.2 0.5 3.6 White 
Black 2.0 0.5 1.9 1.7 2.2 1.0 3.5 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.4 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.0 1.1 1.0 1.1 
Other 2.1 0.6 2.0 1.7 2.6 1.1 3.1 . . . . . . . 1.3 0.4 1.1 1.1 1.7 1.0 1.9 
HLA-DQ type 
2.0 0.5 2.0 1.7 2.3 1.0 3.6 1.1 0.2 1.1 1.0 1.2 0.9 1.3 1.2 0.3 1.1 1.0 1.2 0.6 3.5 X 
DQ2 2.0 0.5 2.0 1.7 2.3 0.9 4.2 1.1 0.1 1.0 1.0 1.2 1.0 1.2 1.1 0.3 1.1 1.0 1.2 0.5 3.6 
DQ8 2.0 0.6 2.0 1.7 2.3 0.8 4.2 1.4 0.6 1.1 1.1 2.0 0.9 2.4 1.2 0.3 1.1 1.0 1.2 0.5 3.1 
DQ2/DQ8 2.1 0.5 2.1 1.8 2.4 0.9 3.9 1.5 0.6 1.5 1.1 1.7 1.0 2.8 1.1 0.3 1.1 1.0 1.1 0.8 2.5 
All 2.0 0.5 2.0 1.7 2.3 0.8 4.2 1.3 0.5 1.1 1.0 1.5 0.9 2.8 1.2 0.3 1.1 1.0 1.2 0.5 3.6 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 36. SI of ISLA_Gad55 in demographics after insulin start 
ISLA_Gad55si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.0 0.5 2.0 1.7 2.3 0.8 3.8 1.9 0.6 1.8 1.6 2.3 1.1 2.6 1.2 0.3 1.1 1.0 1.2 0.6 3.1 Male 
Female 2.0 0.5 2.0 1.7 2.3 0.9 4.2 1.9 0.6 2.0 1.6 2.3 0.9 3.2 1.2 0.3 1.1 1.0 1.2 0.5 3.6 
Race 
2.0 0.5 2.0 1.7 2.3 0.8 4.2 1.9 0.6 2.0 1.6 2.3 0.9 3.2 1.2 0.3 1.1 1.0 1.2 0.5 3.6 White 
Black 2.0 0.5 1.9 1.7 2.2 1.0 3.5 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.4 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.0 1.1 1.0 1.1 
Other 2.1 0.6 2.0 1.7 2.6 1.1 3.1 . . . . . . . 1.3 0.4 1.1 1.1 1.7 1.0 1.9 
HLA-DQ type 
2.0 0.5 2.0 1.7 2.3 1.0 3.6 1.8 0.3 1.8 1.6 2.1 1.6 2.1 1.2 0.3 1.1 1.0 1.2 0.6 3.5 X 
DQ2 2.0 0.5 2.0 1.7 2.3 0.9 4.2 1.3 0.6 1.1 0.9 2.0 0.9 2.0 1.1 0.3 1.1 1.0 1.2 0.5 3.6 
DQ8 2.0 0.6 2.0 1.7 2.3 0.8 4.2 2.1 0.5 2.1 1.6 2.4 1.1 3.2 1.2 0.3 1.1 1.0 1.2 0.5 3.1 
DQ2/DQ8 2.1 0.5 2.1 1.8 2.4 0.9 3.9 . . . . . . . 1.1 0.3 1.1 1.0 1.1 0.8 2.5 
All 2.0 0.5 2.0 1.7 2.3 0.8 4.2 1.9 0.6 2.0 1.6 2.3 0.9 3.2 1.2 0.3 1.1 1.0 1.2 0.5 3.6 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 37. SI of ISLA_PI in demographics before insulin start 
ISLA_PIsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.6 2.1 1.8 2.5 0.8 5.9 1.2 0.3 1.1 1.0 1.2 1.0 2.1 1.2 0.4 1.1 1.0 1.2 0.5 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 0.9 4.3 1.4 0.6 1.1 1.0 1.8 0.9 2.8 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
Race 
2.2 0.6 2.1 1.8 2.5 0.8 5.9 1.3 0.5 1.1 1.0 1.3 0.9 2.8 1.2 0.4 1.1 1.0 1.2 0.4 8.0 White 
Black 2.1 0.6 2.1 1.7 2.4 1.0 3.7 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.1 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.4 1.2 2.0 1.6 2.9 1.1 5.6 . . . . . . . 1.5 0.7 1.1 1.0 1.9 0.9 3.1 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.9 3.9 1.0 0.2 1.0 0.9 1.2 0.9 1.3 1.2 0.4 1.1 1.0 1.2 0.5 7.1 X 
DQ2 2.2 0.7 2.1 1.7 2.5 0.8 5.9 1.0 0.1 1.0 1.0 1.1 1.0 1.1 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
DQ8 2.2 0.6 2.1 1.7 2.5 0.9 4.3 1.4 0.5 1.1 1.0 1.8 1.0 2.3 1.2 0.3 1.1 1.0 1.2 0.5 3.7 
DQ2/DQ8 2.3 0.7 2.2 1.9 2.6 1.0 5.6 1.6 0.7 1.2 1.1 2.1 1.0 2.8 1.2 0.3 1.1 1.0 1.2 0.7 3.0 
All 2.2 0.6 2.1 1.8 2.5 0.8 5.9 1.3 0.5 1.1 1.0 1.3 0.9 2.8 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 38. SI of ISLA_PI in demographics after insulin start 
ISLA_PIsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.6 2.1 1.8 2.5 0.8 5.9 1.8 0.6 1.7 1.5 2.1 1.1 2.7 1.2 0.4 1.1 1.0 1.2 0.5 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 0.9 4.3 2.1 0.6 2.2 1.5 2.6 1.0 3.0 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
Race 
2.2 0.6 2.1 1.8 2.5 0.8 5.9 2.0 0.6 1.9 1.5 2.4 1.0 3.0 1.2 0.4 1.1 1.0 1.2 0.4 8.0 White 
Black 2.1 0.6 2.1 1.7 2.4 1.0 3.7 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.1 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.4 1.2 2.0 1.6 2.9 1.1 5.6 . . . . . . . 1.5 0.7 1.1 1.0 1.9 0.9 3.1 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.9 3.9 2.2 0.6 2.0 1.8 2.6 1.7 3.0 1.2 0.4 1.1 1.0 1.2 0.5 7.1 X 
DQ2 2.2 0.7 2.1 1.7 2.5 0.8 5.9 1.4 0.6 1.1 1.1 2.1 1.1 2.1 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
DQ8 2.2 0.6 2.1 1.7 2.5 0.9 4.3 2.0 0.6 2.0 1.5 2.6 1.0 2.9 1.2 0.3 1.1 1.0 1.2 0.5 3.7 
DQ2/DQ8 2.3 0.7 2.2 1.9 2.6 1.0 5.6 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 3.0 
All 2.2 0.6 2.1 1.8 2.5 0.8 5.9 2.0 0.6 1.9 1.5 2.4 1.0 3.0 1.2 0.4 1.1 1.0 1.2 0.4 8.0 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 39. SI of ISLA_Tep69 in demographics before insulin start 
ISLA_Tep69si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.1 0.5 2.1 1.8 2.4 0.8 4.2 1.2 0.6 1.0 0.9 1.3 0.7 2.7 1.2 0.3 1.1 1.0 1.2 0.7 6.7 Male 
Female 2.1 0.7 2.1 1.8 2.4 0.8 11.9 1.4 0.6 1.1 1.0 1.8 0.9 2.6 1.2 0.3 1.1 1.0 1.2 0.3 6.9 
Race 
2.1 0.6 2.1 1.8 2.4 0.8 11.9 1.3 0.6 1.1 1.0 1.4 0.7 2.7 1.2 0.3 1.1 1.0 1.2 0.3 6.9 White 
Black 2.0 0.6 2.1 1.7 2.3 1.0 3.9 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.9 2.0 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.2 0.6 2.1 1.9 2.6 0.9 3.1 . . . . . . . 1.4 0.5 1.2 1.1 1.9 0.9 2.4 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.8 3.6 1.1 0.2 1.0 1.0 1.2 1.0 1.3 1.2 0.3 1.1 1.0 1.2 0.3 4.0 X 
DQ2 2.1 0.5 2.1 1.8 2.4 0.8 4.3 1.0 0.2 1.0 0.9 1.2 0.7 1.4 1.2 0.4 1.1 1.0 1.2 0.5 6.9 
DQ8 2.1 0.6 2.0 1.7 2.4 0.8 4.2 1.4 0.7 1.1 1.0 2.1 0.8 2.7 1.2 0.3 1.1 1.0 1.2 0.5 3.2 
DQ2/DQ8 2.2 0.9 2.1 1.9 2.5 1.0 11.9 1.6 0.7 1.2 1.0 2.1 0.9 2.6 1.2 0.4 1.1 1.0 1.2 0.8 6.7 
All 2.1 0.6 2.1 1.8 2.4 0.8 11.9 1.3 0.6 1.1 1.0 1.4 0.7 2.7 1.2 0.3 1.1 1.0 1.2 0.3 6.9 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 40. SI of ISLA_Tep69 in demographics after insulin start 
ISLA_Tep69si 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.1 0.5 2.1 1.8 2.4 0.8 4.2 2.0 0.7 1.9 1.4 2.7 1.1 3.0 1.2 0.3 1.1 1.0 1.2 0.7 6.7 Male 
Female 2.1 0.7 2.1 1.8 2.4 0.8 11.9 2.0 0.6 2.1 1.6 2.4 1.0 2.9 1.2 0.3 1.1 1.0 1.2 0.3 6.9 
Race 
2.1 0.6 2.1 1.8 2.4 0.8 11.9 2.0 0.6 2.1 1.6 2.4 1.0 3.0 1.2 0.3 1.1 1.0 1.2 0.3 6.9 White 
Black 2.0 0.6 2.1 1.7 2.3 1.0 3.9 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.9 2.0 
Asian . . . . . . . . . . . . . . 1.1 0.0 1.1 1.1 1.1 1.1 1.1 
Other 2.2 0.6 2.1 1.9 2.6 0.9 3.1 . . . . . . . 1.4 0.5 1.2 1.1 1.9 0.9 2.4 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.8 3.6 2.0 0.3 2.0 1.7 2.3 1.7 2.3 1.2 0.3 1.1 1.0 1.2 0.3 4.0 X 
DQ2 2.1 0.5 2.1 1.8 2.4 0.8 4.3 1.4 0.6 1.1 1.0 2.1 1.0 2.1 1.2 0.4 1.1 1.0 1.2 0.5 6.9 
DQ8 2.1 0.6 2.0 1.7 2.4 0.8 4.2 2.1 0.6 2.2 1.6 2.7 1.0 3.0 1.2 0.3 1.1 1.0 1.2 0.5 3.2 
DQ2/DQ8 2.2 0.9 2.1 1.9 2.5 1.0 11.9 . . . . . . . 1.2 0.4 1.1 1.0 1.2 0.8 6.7 
All 2.1 0.6 2.1 1.8 2.4 0.8 11.9 2.0 0.6 2.1 1.6 2.4 1.0 3.0 1.2 0.3 1.1 1.0 1.2 0.3 6.9 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 41. SI of MIP_Abbos in demographics before insulin start 
MIP_Abbossi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.9 2.1 1.8 2.5 0.8 18.5 1.3 0.5 1.1 1.0 1.2 0.8 2.6 1.2 0.4 1.1 1.0 1.2 0.7 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 0.9 4.2 1.4 0.6 1.1 1.0 1.9 0.9 2.9 1.2 0.3 1.1 1.0 1.2 0.5 4.1 
Race 
2.2 0.8 2.1 1.8 2.5 0.8 18.5 1.4 0.6 1.1 1.0 1.5 0.8 2.9 1.2 0.3 1.1 1.0 1.2 0.5 7.1 White 
Black 2.1 0.6 2.1 1.8 2.4 1.0 3.8 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.1 
Asian . . . . . . . . . . . . . . 1.0 0.0 1.0 1.0 1.1 1.0 1.1 
Other 2.3 0.7 2.2 2.0 3.0 1.0 3.4 . . . . . . . 1.4 0.4 1.2 1.1 1.8 0.9 2.2 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 1.0 3.8 1.1 0.1 1.1 1.0 1.2 0.9 1.2 1.2 0.4 1.1 1.0 1.2 0.6 7.1 X 
DQ2 2.1 0.6 2.1 1.8 2.5 0.9 4.4 1.1 0.2 1.1 1.0 1.2 0.9 1.5 1.2 0.3 1.1 1.0 1.2 0.5 4.1 
DQ8 2.2 1.0 2.1 1.7 2.5 0.8 18.5 1.4 0.6 1.1 1.0 2.1 0.8 2.6 1.2 0.3 1.1 1.0 1.2 0.6 3.2 
DQ2/DQ8 2.3 0.6 2.2 1.9 2.6 0.9 4.4 1.6 0.7 1.2 1.0 1.9 0.9 2.9 1.2 0.3 1.1 1.0 1.2 0.7 2.8 
All 2.2 0.8 2.1 1.8 2.5 0.8 18.5 1.4 0.6 1.1 1.0 1.5 0.8 2.9 1.2 0.3 1.1 1.0 1.2 0.5 7.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 42. SI of MIP_Abbos in demographics after insulin start 
MIP_Abbossi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.9 2.1 1.8 2.5 0.8 18.5 2.0 0.8 1.9 1.5 2.6 1.1 3.1 1.2 0.4 1.1 1.0 1.2 0.7 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 0.9 4.2 2.1 0.6 2.3 1.6 2.6 1.1 3.0 1.2 0.3 1.1 1.0 1.2 0.5 4.1 
Race 
2.2 0.8 2.1 1.8 2.5 0.8 18.5 2.1 0.6 2.3 1.6 2.6 1.1 3.1 1.2 0.3 1.1 1.0 1.2 0.5 7.1 White 
Black 2.1 0.6 2.1 1.8 2.4 1.0 3.8 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.8 2.1 
Asian . . . . . . . . . . . . . . 1.0 0.0 1.0 1.0 1.1 1.0 1.1 
Other 2.3 0.7 2.2 2.0 3.0 1.0 3.4 . . . . . . . 1.4 0.4 1.2 1.1 1.8 0.9 2.2 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 1.0 3.8 2.0 0.4 2.1 1.7 2.4 1.5 2.4 1.2 0.4 1.1 1.0 1.2 0.6 7.1 X 
DQ2 2.1 0.6 2.1 1.8 2.5 0.9 4.4 1.5 0.7 1.2 1.1 2.3 1.1 2.3 1.2 0.3 1.1 1.0 1.2 0.5 4.1 
DQ8 2.2 1.0 2.1 1.7 2.5 0.8 18.5 2.2 0.6 2.3 1.6 2.7 1.1 3.1 1.2 0.3 1.1 1.0 1.2 0.6 3.2 
DQ2/DQ8 2.3 0.6 2.2 1.9 2.6 0.9 4.4 . . . . . . . 1.2 0.3 1.1 1.0 1.2 0.7 2.8 
All 2.2 0.8 2.1 1.8 2.5 0.8 18.5 2.1 0.6 2.3 1.6 2.6 1.1 3.1 1.2 0.3 1.1 1.0 1.2 0.5 7.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 43. SI of MIP_BSA in demographics before insulin start 
MIP_BSAsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.6 2.1 1.8 2.5 0.8 4.5 1.3 0.5 1.1 1.0 1.3 0.9 2.5 1.2 0.4 1.1 1.0 1.2 0.6 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 1.0 4.1 1.4 0.6 1.1 1.0 1.8 0.9 2.7 1.2 0.3 1.1 1.0 1.2 0.7 4.7 
Race 
2.2 0.6 2.1 1.8 2.5 0.8 4.5 1.4 0.6 1.1 1.0 1.5 0.9 2.7 1.2 0.3 1.1 1.0 1.2 0.6 7.1 White 
Black 2.1 0.5 2.1 1.8 2.3 1.0 3.9 . . . . . . . 1.2 0.3 1.1 1.0 1.3 0.7 2.3 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 2.3 0.7 2.3 2.0 2.8 1.0 3.2 . . . . . . . 1.4 0.4 1.2 1.1 1.8 1.0 2.0 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.9 4.1 1.1 0.2 1.0 1.0 1.2 0.9 1.3 1.2 0.3 1.1 1.0 1.2 0.7 3.6 X 
DQ2 2.2 0.6 2.1 1.8 2.4 0.9 4.1 1.1 0.2 1.0 1.0 1.2 0.9 1.5 1.2 0.4 1.1 1.0 1.2 0.7 7.1 
DQ8 2.1 0.6 2.1 1.8 2.5 0.8 4.5 1.5 0.7 1.1 1.0 2.2 1.0 2.7 1.2 0.3 1.1 1.0 1.2 0.6 4.7 
DQ2/DQ8 2.3 0.6 2.2 1.9 2.7 0.8 4.5 1.5 0.6 1.2 1.0 1.9 0.9 2.7 1.1 0.3 1.1 1.0 1.1 0.8 2.9 
All 2.2 0.6 2.1 1.8 2.5 0.8 4.5 1.4 0.6 1.1 1.0 1.5 0.9 2.7 1.2 0.3 1.1 1.0 1.2 0.6 7.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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Table 44. SI of MIP_BSA in demographics after insulin start 
MIP_BSAsi 
New Onsets FDR-converter FDR-nonconverter 
Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max Mean Std Median Q1 Q3 Min Max 
Gender 
2.2 0.6 2.1 1.8 2.5 0.8 4.5 2.0 0.7 2.0 1.4 2.5 1.1 2.9 1.2 0.4 1.1 1.0 1.2 0.6 7.1 Male 
Female 2.2 0.6 2.1 1.8 2.5 1.0 4.1 2.1 0.6 2.2 1.6 2.6 1.1 2.8 1.2 0.3 1.1 1.0 1.2 0.7 4.7 
Race 
2.2 0.6 2.1 1.8 2.5 0.8 4.5 2.1 0.6 2.2 1.6 2.5 1.1 2.9 1.2 0.3 1.1 1.0 1.2 0.6 7.1 White 
Black 2.1 0.5 2.1 1.8 2.3 1.0 3.9 . . . . . . . 1.2 0.3 1.1 1.0 1.3 0.7 2.3 
Asian . . . . . . . . . . . . . . 1.1 0.1 1.1 1.0 1.1 1.0 1.1 
Other 2.3 0.7 2.3 2.0 2.8 1.0 3.2 . . . . . . . 1.4 0.4 1.2 1.1 1.8 1.0 2.0 
HLA-DQ type 
2.1 0.5 2.1 1.8 2.4 0.9 4.1 2.1 0.3 2.1 1.8 2.3 1.7 2.3 1.2 0.3 1.1 1.0 1.2 0.7 3.6 X 
DQ2 2.2 0.6 2.1 1.8 2.4 0.9 4.1 1.6 0.7 1.2 1.1 2.3 1.1 2.3 1.2 0.4 1.1 1.0 1.2 0.7 7.1 
DQ8 2.1 0.6 2.1 1.8 2.5 0.8 4.5 2.2 0.6 2.3 1.6 2.7 1.1 2.9 1.2 0.3 1.1 1.0 1.2 0.6 4.7 
DQ2/DQ8 2.3 0.6 2.2 1.9 2.7 0.8 4.5 . . . . . . . 1.1 0.3 1.1 1.0 1.1 0.8 2.9 
All 2.2 0.6 2.1 1.8 2.5 0.8 4.5 2.1 0.6 2.2 1.6 2.5 1.1 2.9 1.2 0.3 1.1 1.0 1.2 0.6 7.1 
Std = standard deviation;   Q1 = lower quartile;   Q3 = uppper quartile 
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B.1.2 SI of ten test antigens over time by subpopulations 
Based on the insulin start date, two subgroup of FDR-converters stratified, SI of ten test antigens 
plotted into two parts for one test antigens, which means FDR-converter with using insulin and 
FDR-converter without using insulin compared to other subpopulations separately.  
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 Figure 21. Chang in SI over time for CNSA_EX2 
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Figure 22. Chang in SI over time for CNSA_MBP 
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Figure 23. Chang in SI over time for GLIA_GFAP 
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Figure 24. Chang in SI over time for GLIA_S100 
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Figure 25. Chang in SI over time for ISLA_Gad 
85 
ISLA_Gad55si 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Time Windows/ Month
0 3 6 9 12 15 18 21 24
SI of ISLA_Gad55si overtime before insulin start in FDR-converter compare with other subpopulations
AGS New Onsets FDR-converter FDR-nonconverter
ISLA_Gad55si 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Time Windows/ Month
0 3 6 9 12 15 18 21 24
SI of ISLA_Gad55si overtime after insulin start in FDR-converter compare with other subpopulations
AGS New Onsets FDR-converter FDR-nonconverter
 
Figure 26. Chang in SI over time for ISLA_Gad55 
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Figure 27. Chang in SI over time for ISLA_PI 
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Figure 28. Chang in SI over time for ISLA_Tep69 
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Figure 29. Chang in SI over time for MIP_Abbos 
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Figure 30. Chang in SI over time for MIP_BSA 
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B.1.3 Optimal cutoff for ten test antigens 
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Figure 31. ROC curve at different cutoffs for CNSA_EX2 
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Figure 32. ROC curve at different cutoffs for CNSA_MBP 
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Figure 33. ROC curve at different cutoffs for GLIA_GFAP 
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Figure 34. ROC curve at different cutoffs for GLIA_S100 
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Figure 35. ROC curve at different cutoffs for ISLA_Gad 
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Figure 36. ROC curve at different cutoffs for ISLA_Gad55 
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Figure 37. ROC curve at different cutoffs for ISLA_PI 
 
97 
TP_RATE
0
10
20
30
40
50
60
70
80
90
100
FP_RATE
0 10 20 30 40 50 60 70 80 90 100
ROC Curve with Different Cutoff for ISLA_Tep69si
CUTOFF 0.500 0.625 0.750
0.875 1.000 1.125
1.250 1.375 1.500
1.625 1.750 1.875
2.000 2.125 2.250
2.375 2.500 2.625
2.750 2.875 3.000
 
Figure 38. ROC curve at different cutoffs for ISLA_Tep69 
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Figure 39. ROC curve at different cutoffs for MIP_Abbos 
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Figure 40. ROC curve at different cutoffs for MIP_BSA 
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